Efficacy and Safety of Oral Semaglutide versus Empagliflozin in Subjects with Type 2 Diabetes Mellitus. A 52-week Randomised, Open-label, Active-controlled Trial

Trial Profile

Efficacy and Safety of Oral Semaglutide versus Empagliflozin in Subjects with Type 2 Diabetes Mellitus. A 52-week Randomised, Open-label, Active-controlled Trial

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Semaglutide (Primary) ; Empagliflozin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms PIONEER 2
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 30 Jun 2017 Planned End Date changed from 13 Mar 2018 to 12 Mar 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 09 Mar 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top